Sectoral Asset Management Inc Alnylam Pharmaceuticals, Inc. Transaction History

Sectoral Asset Management Inc

$88.5 Million
Q1 2025

A detailed history of Sectoral Asset Management Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Sectoral Asset Management Inc holds 5,205 shares of ALNY stock, worth $1.57 Million. This represents 1.59% of its overall portfolio holdings.

Number of Shares

5,205

Previous 8,300 37.29%

Holding current value

$1.57 Million

Previous $1.95 Million 28.06%

% of portfolio

1.59%

Previous 1.96%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$233.07 - $290.7 $721,351 - $899,716	-3,095 Reduced 37.29%	5,205 $1.41 Million
Q4 2024 Feb 14, 2025	SELL	$232.27 - $300.43 $322,855 - $417,597	-1,390 Reduced 14.34%	8,300 $1.95 Million
Q3 2024 Nov 14, 2024	SELL	$233.81 - $287.01 $652,329 - $800,757	-2,790 Reduced 22.36%	9,690 $2.67 Million
Q2 2024 Aug 13, 2024	SELL	$143.31 - $247.0 $856,993 - $1.48 Million	-5,980 Reduced 32.39%	12,480 $3.03 Million
Q1 2024 May 14, 2024	SELL	$146.51 - $198.2 $612,411 - $828,476	-4,180 Reduced 18.46%	18,460 $2.76 Million
Q4 2023 Feb 14, 2024	SELL	$151.41 - $196.57 $956,911 - $1.24 Million	-6,320 Reduced 21.82%	22,640 $4.33 Million
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $147,886 - $183,288	-866 Reduced 2.9%	28,960 $5.13 Million
Q2 2023 Aug 11, 2023	BUY	$185.01 - $212.05 $602,392 - $690,434	3,256 Added 12.25%	29,826 $5.67 Million
Q1 2023 May 12, 2023	BUY	$182.66 - $235.53 $686,801 - $885,592	3,760 Added 16.48%	26,570 $5.32 Million
Q4 2022 Feb 10, 2023	BUY	$185.53 - $241.31 $24,118 - $31,370	130 Added 0.57%	22,810 $5.42 Million
Q3 2022 Nov 10, 2022	BUY	$138.54 - $232.0 $1.48 Million - $2.47 Million	10,650 Added 88.53%	22,680 $4.54 Million
Q2 2022 Aug 15, 2022	BUY	$120.42 - $169.29 $958,543 - $1.35 Million	7,960 Added 195.58%	12,030 $1.76 Million
Q1 2022 May 10, 2022	SELL	$127.18 - $173.91 $448,436 - $613,206	-3,526 Reduced 46.42%	4,070 $665,000
Q4 2021 Feb 11, 2022	SELL	$159.56 - $209.29 $10.9 Million - $14.3 Million	-68,250 Reduced 89.98%	7,596 $1.29 Million
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $339,500 - $415,460	-2,000 Reduced 2.57%	75,846 $14.3 Million
Q2 2021 Aug 16, 2021	SELL	$128.63 - $176.89 $4.1 Million - $5.64 Million	-31,900 Reduced 29.07%	77,846 $13.2 Million
Q1 2021 May 14, 2021	BUY	$126.83 - $175.69 $177,562 - $245,966	1,400 Added 1.29%	109,746 $15.5 Million
Q4 2020 Feb 12, 2021	BUY	$122.97 - $147.0 $13.3 Million - $15.9 Million	108,346 New	108,346 $14.1 Million
Q3 2020 Nov 13, 2020	SELL	$121.19 - $165.49 $2.13 Million - $2.91 Million	-17,600 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$104.21 - $156.44 $6.27 Million - $9.42 Million	-60,200 Reduced 77.38%	17,600 $2.61 Million
Q1 2020 May 13, 2020	SELL	$93.12 - $133.99 $912,576 - $1.31 Million	-9,800 Reduced 11.19%	77,800 $8.47 Million
Q4 2019 Feb 12, 2020	SELL	$74.51 - $124.23 $7.21 Million - $12 Million	-96,741 Reduced 52.48%	87,600 $10.1 Million
Q3 2019 Nov 14, 2019	SELL	$70.9 - $87.82 $15.5 Million - $19.2 Million	-218,300 Reduced 54.22%	184,341 $14.8 Million
Q2 2019 Aug 14, 2019	BUY	$65.86 - $92.79 $763,976 - $1.08 Million	11,600 Added 2.97%	402,641 $29.2 Million
Q1 2019 May 14, 2019	SELL	$72.76 - $93.45 $7.59 Million - $9.75 Million	-104,300 Reduced 21.06%	391,041 $36.5 Million
Q4 2018 Feb 12, 2019	BUY	$62.67 - $88.33 $6.98 Million - $9.83 Million	111,300 Added 28.98%	495,341 $36.1 Million
Q3 2018 Nov 14, 2018	BUY	$87.52 - $122.67 $7.03 Million - $9.86 Million	80,341 Added 26.45%	384,041 $33.6 Million
Q2 2018 Aug 13, 2018	BUY	$88.31 - $107.8 $26.8 Million - $32.7 Million	303,700 New	303,700 $29.9 Million

Others Institutions Holding ALNY

# of Institutions

720

Shares Held

111M

Call Options Held

978K

Put Options Held

881K

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $37.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sectoral Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Sectoral Asset Management Inc with notifications on news.

Account

Sectoral Asset Management Inc Alnylam Pharmaceuticals, Inc. Transaction History